Rockwell medical, inc. (RMTI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows From Operating Activities:
Net Loss

-34,128

-32,125

-25,921

-19,802

-14,420

-21,327

-48,783

-54,021

-21,444

-2,683

-5,501

Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization

788

650

514

762

822

996

1,007

1,087

1,176

1,389

1,233

Share Based Compensation - Non-employee

-

-

-

-

-

-

1,862

2,322

312

639

-

Share Based Compensation - Non-employee

-

-

-

-

-

-

-

-

-

-

403

Stock-based Compensation

4,951

4,387

7,174

10,346

8,887

10,094

5,849

4,979

4,065

3,381

1,949

Research and Development - Licenses Acquired (Related Party)

0

1,100

-

-

-

-

-

-

-

-

-

Increase in Inventory Reserves

1,271

8,784

-

-

-

-

-

-

-

-

-

Amortization of Right of Use Asset

1,864

-

-

-

-

-

-

-

-

-

-

Restricted Stock Retained in Satisfaction of Tax Liabilities

-

-

-

-

-2,912

-

-

-

-

-

-

Loss on Disposal of Assets

-4

-4

-10

-8

-5

-7

-16

-17

-29

-19

-36

Realized (Gain) Loss on Sale of Investments Available-for-Sale

30

-222

-

-

-

-

-

-

-

-

-

Amortization of Debt Issuance Costs

-

-

-

-

-

882

227

-

-

-

-

Non-cash Interest Expense

-

-

-

-

-

874

225

-

-

-

-

Realized (Gain) on Sale of Investments Available-for-Sale

-

-

-792

-26

-58

-

-

67

-

-

-

Foreign Currency Translation Adjustment

0

10

-

-

-

-

-

-

-

-

-

Foreign Currency Translation Adjustment

-

-

1

-

-

-

-

-

-

-

-

(Gain) on Sale of Investments Available for Sale

-

-

-

-

-

1

-

-

84

-

-

Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable, net

-2,776

623

-

-

-

-

-

-

-

-

-

Decrease in Accounts Receivable

-

-

962

1,162

574

-106

146

209

-284

1,014

-1,737

Decrease in Insurance Receivable

-371

371

-

-

-

-

-

-

-

-

-

(Increase) Decrease in Inventory

-316

835

-343

6,095

3,951

1,120

150

145

-432

-151

-73

Decrease (Increase) in Other Assets

-933

165

-264

1,230

360

13

-669

-1,855

2,457

690

-68

Increase in Accounts Payable

-1,473

269

-1,636

1,863

-1,299

-3,391

-6,147

9,469

1,705

270

-1,822

Decrease in Settlement Payable

-312

416

-

-

-

-

-

-

-

-

-

Decrease in Lease Liability

1,803

-

-

-

-

-

-

-

-

-

-

Increase in Other Liabilities

-532

271

634

191

-413

-2,345

-5,295

3,829

5,028

637

395

Decrease in Deferred License Revenue

-2,252

-2,394

-2,328

-

-

-

-

-

-

-

-

(Decrease) in Deferred License Revenue

-

-

-

-2,065

-2,081

19,492

-

-

-

-

-

Increase (decrease) in Deferred International Partnership Revenue

-

-

-

4,706

-

-

-

-

-

-

-

Changes in Assets and Liabilities

1,975

3,432

3,684

3,793

8,681

-12,727

11,069

-14,799

-4,993

645

-451

Cash Used In Operating Activities

-27,254

-20,419

-21,112

-12,452

-13,328

4,257

-50,664

-30,746

-10,783

2,100

-1,426

Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale

-41,677

-20,178

-35,733

-

-

-

-

-

-

-

-

Purchase of Securities Available for Sale

-

-

-

25,781

21,800

13,100

12,002

2,012

2,000

12,151

-

Sale of Investments Available-for-Sale

38,265

33,895

51,918

24,491

1,468

4,976

-

14,037

1,975

-

-

Purchase of Equipment

587

744

1,682

355

815

684

654

507

421

772

1,595

Purchase of Research and Development Licenses (Related Party)

750

250

-

-

-

-

-

-

-

-

-

Proceeds on Sale of Assets

0

0

0

1

4

-

6

1

2

1

-

Purchase of Intangible Assets

-

-

-

-

-

-

-

-

145

-

4

Cash Provided By Investing Activities

-4,749

12,723

14,502

-1,644

-21,141

-8,808

-12,649

11,518

-587

-12,922

-1,600

Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Shares and Purchase Warrants

-

-

-

80

2,780

79,569

51,596

18,231

4,841

90

-

Proceeds from the Issuance of Notes Payable

-

-

-

-

-

-

20,000

-

-

-

-

Debt Issuance Costs

-

-

-

-

-

-

1,109

-

-

-

-

Payments on Short Term Note Payable

1,145

0

-

-

-

-

-

-

18

43

181

Payments on Notes Payable and Capital Lease Obligations

-

-

-

-

-

21,100

2

6

-

-

-

Proceeds from the Issuance of Common Stock / Public Offering

-

-

123

-

-

-

-

-

-

-

20,650

Proceeds from the Exercise of Employee Stock Options

147

67

-

-

-

-

-

-

-

-

-

Repurchase of Common Shares to Pay Employee Withholding Taxes

-279

0

-2,287

-

-

-

-

-

-

-

-

Cash Provided By Financing Activities

21,084

22,003

-2,163

80

-132

58,469

70,484

18,224

4,822

46

20,469

(Decrease) Increase In Cash and Cash Equivalents

-10,919

14,307

-

-

-

-

-

-

-

-

-

Effects of Exchange Rate Changes

-

-

-

-0

-

-

-

-

-

-

-

Decrease In Cash and Cash Equivalents

-

-

-8,773

-14,017

-34,602

53,919

7,169

-1,003

-6,548

-10,774

17,441

Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale

-10

109

866

-

-

-

-

-

-

-

-

Research and Development Licenses (Related Party)

0

850

-

-

-

-

-

-

-

-

-

Insurance Financing Note Payable

763

0

-

-

-

-

-

-

-

-

-

Interest Paid

-

-

-

-

-

3,518

1,154

0

1

9

25

Income Taxes Paid

-

-

-

404

-

-

-

-

-

-

-

Non-Cash Investing and Financing Activity - Acquisition of Intangible Assets

-

-

-

-

-

-

-

-

550

-

-

Equipment Acquired Under Capital Lease Obligations

-

-

-

-

-

-

-

-

-

8

-

Equipment Acquired Under Capital Lease Obligations

-

-

-

-

-

-

-

-

-

-

25

Public-offering
Proceeds from the Issuance of Common Stock / Public Offering

18,777

22,000

-

-

-

-

-

-

-

-

-

Offering Costs from the Issuance of Common Stock / Public Offering

1,489

64

-

-

-

-

-

-

-

-

-

At -the-market
Proceeds from the Issuance of Common Stock / Public Offering

5,383

0

-

-

-

-

-

-

-

-

-

Offering Costs from the Issuance of Common Stock / Public Offering

309

0

-

-

-

-

-

-

-

-

-